Zachary Klaassen1, Lauren E Howard2,3, Amanda de Hoedt2, Christopher L Amling4, William J Aronson5,6, Matthew R Cooperberg7,8, Christopher J Kane9,10, Martha K Terris1,11, Stephen J Freedland2,12. 1. Department of Surgery, Section of Urology, Medical College of Georgia, Augusta University, Augusta, Georgia. 2. Department of Surgery, Division of Urology, Durham Veterans Affairs Medical Center, Durham, North Carolina. 3. Department of Surgery, Division of Urologic Surgery, Duke University Medical Center, Durham, North Carolina. 4. Department of Urology, Oregon Health and Sciences University, Portland, Oregon. 5. Department of Surgery, Division of Urolog, West Los Angeles Veterans Affairs Medical Center, West Los Angeles, California. 6. Department of Urology, University of California at Los Angeles School of Medicine, Los Angeles, California. 7. Department of Surgery, Division of Urology, San Francisco Veterans Affairs Medical Center, San Francisco, California. 8. Department of Urology, University of California at San Francisco, San Francisco, California. 9. Department of Surgery, Division of Urology, San Diego Veterans Affairs Medical Center, San Diego, California. 10. Department of Urology, University of California at San Diego, San Diego, California. 11. Department of Surgery, Division of Urology, Augusta Veterans Affairs Medical Center, Augusta, Georgia. 12. Department of Surgery, Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California.
Abstract
BACKGROUND: Skeletal-related events (SREs) are common complications of bone metastatic castration-resistant prostate cancer (mCRPC). To the authors' knowledge, there are limited data regarding which factors predict SREs. The authors identified risk factors for SREs in men with bone mCRPC using characteristics commonly available in the medical record. METHODS: Data from 454 patients with nonmetastatic CRPC were identified from 2 Veteran Affairs Medical Centers from 2000 through 2013. Among these men, 233 (51%) developed bone metastases during follow-up and represented the study cohort. First occurrence of an SRE was abstracted from the medical records. A stepwise multivariable Cox model was used to select the strongest predictors of time to SRE. RESULTS: The median age of the patients at the time of diagnosis of bone mCRPC was 75 years (interquartile range, 68-81 years), and there were 153 nonblack patients (66%). During follow-up (median, 7.8 months [interquartile range, 2.9-18.3 months]), 88 patients (38%) had an SRE. On univariable analysis, more recent year of metastasis (hazard ratio [HR], 0.91), prostate-specific antigen doubling time of ≥9 months versus <9 months (HR, 0.50), and bone pain (HR, 3.34) were all found to be associated with SRE risk. On multivariable analysis, year of metastasis (HR, 0.93), biopsy Gleason score of 7 versus ≤6 (HR, 1.74), radiotherapy as the primary localized treatment versus none (HR, 2.33), and bone pain (HR, 3.64) were associated with SRE risk. The area under the curve for a multivariable model based upon these risk factors was 0.744. CONCLUSIONS: The authors identified several significant predictors of SREs among men with mCRPC. In particular, men with bone pain are at high risk of an SRE. If confirmed, future trials should focus on prolonging life and reducing SRE risk in patients with mCRPC with bone pain. Cancer 2017;123:1528-1535.
BACKGROUND: Skeletal-related events (SREs) are common complications of bone metastatic castration-resistant prostate cancer (mCRPC). To the authors' knowledge, there are limited data regarding which factors predict SREs. The authors identified risk factors for SREs in men with bone mCRPC using characteristics commonly available in the medical record. METHODS: Data from 454 patients with nonmetastatic CRPC were identified from 2 Veteran Affairs Medical Centers from 2000 through 2013. Among these men, 233 (51%) developed bone metastases during follow-up and represented the study cohort. First occurrence of an SRE was abstracted from the medical records. A stepwise multivariable Cox model was used to select the strongest predictors of time to SRE. RESULTS: The median age of the patients at the time of diagnosis of bone mCRPC was 75 years (interquartile range, 68-81 years), and there were 153 nonblack patients (66%). During follow-up (median, 7.8 months [interquartile range, 2.9-18.3 months]), 88 patients (38%) had an SRE. On univariable analysis, more recent year of metastasis (hazard ratio [HR], 0.91), prostate-specific antigen doubling time of ≥9 months versus <9 months (HR, 0.50), and bone pain (HR, 3.34) were all found to be associated with SRE risk. On multivariable analysis, year of metastasis (HR, 0.93), biopsy Gleason score of 7 versus ≤6 (HR, 1.74), radiotherapy as the primary localized treatment versus none (HR, 2.33), and bone pain (HR, 3.64) were associated with SRE risk. The area under the curve for a multivariable model based upon these risk factors was 0.744. CONCLUSIONS: The authors identified several significant predictors of SREs among men with mCRPC. In particular, men with bone pain are at high risk of an SRE. If confirmed, future trials should focus on prolonging life and reducing SRE risk in patients with mCRPC with bone pain. Cancer 2017;123:1528-1535.
Authors: Florian Roghmann; Carina Antczak; Rana R McKay; Toni Choueiri; Jim C Hu; Adam S Kibel; Simon P Kim; Keith J Kowalczyk; Mani Menon; Paul L Nguyen; Fred Saad; Jesse D Sammon; Marianne Schmid; Shyam Sukumar; Maxine Sun; Joachim Noldus; Quoc-Dien Trinh Journal: Urol Oncol Date: 2014-10-30 Impact factor: 3.498
Authors: Karim Fizazi; Howard I Scher; Kurt Miller; Ethan Basch; Cora N Sternberg; David Cella; David Forer; Mohammad Hirmand; Johann S de Bono Journal: Lancet Oncol Date: 2014-08-04 Impact factor: 41.316
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Michael S Cookson; Bruce J Roth; Philipp Dahm; Christine Engstrom; Stephen J Freedland; Maha Hussain; Daniel W Lin; William T Lowrance; Mohammad Hassan Murad; William K Oh; David F Penson; Adam S Kibel Journal: J Urol Date: 2013-05-09 Impact factor: 7.450
Authors: L E Howard; A M De Hoedt; W J Aronson; C J Kane; C L Amling; M R Cooperberg; M K Terris; C H Divers; A Valderrama; S J Freedland Journal: Prostate Cancer Prostatic Dis Date: 2016-07-05 Impact factor: 5.554
Authors: D M Moreira; L E Howard; K N Sourbeer; H S Amarasekara; L C Chow; D C Cockrell; B T Hanyok; C L Pratson; W J Aronson; C J Kane; M K Terris; C L Amling; M R Cooperberg; A Liede; S J Freedland Journal: Prostate Cancer Prostatic Dis Date: 2015-05-26 Impact factor: 5.554
Authors: M R Smith; R E Coleman; L Klotz; K Pittman; P Milecki; S Ng; K N Chi; A Balakumaran; R Wei; H Wang; A Braun; K Fizazi Journal: Ann Oncol Date: 2014-11-25 Impact factor: 32.976
Authors: Ingrid Lorese Tablazon; Lauren E Howard; Amanda M De Hoedt; William J Aronson; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Martha K Terris; Stephen J Freedland; Stephen B Williams Journal: Cancer Date: 2019-08-07 Impact factor: 6.860
Authors: Charles J Ryan; E David Crawford; Neal D Shore; Willie Underwood; Mary-Ellen Taplin; Anil Londhe; Peter St John Francis; Jennifer Phillips; Tracy McGowan; Philip W Kantoff Journal: J Urol Date: 2018-04-06 Impact factor: 7.450
Authors: Alison Tse Kawai; David Martinez; Catherine W Saltus; Zdravko P Vassilev; Montse Soriano-Gabarró; James A Kaye Journal: Prostate Cancer Date: 2019-07-09
Authors: Antonio Jose Martin-Perez; María Fernández-González; Paula Postigo-Martin; Marc Sampedro Pilegaard; Carolina Fernández-Lao; Eduardo Castro-Martín; Lydia Martín-Martín; Mario Lozano-Lozano Journal: Int J Environ Res Public Health Date: 2021-04-10 Impact factor: 3.390
Authors: Dionna Jacobson; Benoit Cadieux; Celestia S Higano; David H Henry; Basia A Bachmann; Marko Rehn; Alison T Stopeck; Hossam Saad Journal: J Bone Oncol Date: 2022-03-17 Impact factor: 4.072